Inflammatory Bowel Disease Flashcards
What are the two main diseases that come under Inflammatory Bowel Disease?
Ulcerative Colitis
Crohn’s Disease
What is the underlying pathogenesis of these diseases based on?
It boils down to a defective interaction between the mucosal immunesystem and gut flora
What type of IBD is obesity a risk factor for?
Crohn’s Disease
Which T cell responses are involved in:
a. Ulcerative Colitis
b. Crohn’s Disease
a. Ulcerative Colitis
Th2
b. Crohn’s Disease
Th1
What are the main cytokines in:
a. Ulcerative Colitis
b. Crohn’s Disease
a. Ulcerative Colitis
IL-5
IL-13
b. Crohn’s Disease
TNF-alpha
Which layers of the gut are affected in:
a. Ulcerative Colitis
b. Crohn’s Disease
a. Ulcerative Colitis
Mucosa + Submucosa
b. Crohn’s Disease
All Layers
Describe which regions of the gut are affected in:
a. Ulcerative Colitis
b. Crohn’s Disease
a. Ulcerative Colitis
Starts at the rectum and proceeds proximally (continuous inflammation)
b. Crohn’s Disease
Can be anywhere on the GI tract (mouth to anus)
Patchy inflammation
Are abscesses, fissures and fistulae common in:
a. Ulcerative Colitis
b. Crohn’s Disease
a. Ulcerative Colitis
No
b. Crohn’s Disease
Yes
Describe the effectiveness of surgery in:
a. Ulcerative
b. Crohn’s Disease
a. Ulcerative Colitis
Curative
b. Crohn’s Disease
Not always curative, even if the affected area is cut out, it often reoccurs
Describe some supportive therapies that are given for IBD
Nutritional therapy
Fluid/electrolytes
Potentially even blood transfusions/oral iron
What are the three types of classic symptomatic treatment for IBD?
Aminosalicylates
Glucocorticoids
Immunosuppressants
What is the main aminosalicylate drug?
Mesalazine
AKA 5-aminosalicylic acid (5-ASA)
What is a slightly more complex aminosalicylate?
Olsalazine (this is 2 x 5-ASA)
What type of drug are aminosalicylates?
Anti-inflammatory
Describe the mechanism of anti-inflammatory action of aminosalicylates.
They inhibit IL-1, TNF-alpha and PAF
Decrease antibody secretion
Reduced cell migration (macrophages)
Localised inhibition of immune responses